Human Mass Balance Study With Bilastine

Inclusion Criteria: * No clinically important abnormal physical findings. * No clinically significant abnormalities in the results of laboratory evaluation. * Normal ECG. * Normal supine blood pressure and heart rate. * Body weight between 50 and 100 kg and body mass index between 18 and 30 kg/m2. * Able to communicate well with the investigator and to comply with the requirements of the entire study. * Provision of written informed consent to participate. * Subjects must agree to use an adequate method of contraception during the study and for 12 weeks after dosing. * Subjects must have a negative urine screen for drugs of abuse. * Subjects must have a regular bowel habit. Exclusion Criteria: * Administration of any IMP within 12 weeks before entry to the study. * Use of any prescribed medication or St John's Wort within 14 days or OTC medication within 5 days of dosing. * Existence of any surgical or medical condition which, in the judgement of the investigator, might interfere with the absorption, distribution, metabolism or excretion of the IMP. * History of any drug or alcohol abuse in the past 2 years, or alcohol consumption greater than 21 units per week. * Presence or history of allergy requiring treatment. * Hayfever is allowed unless it is active or has required treatment within the previous 2 months. * Donation or loss of greater than 400 mL of blood within 12 weeks before entry to the study. * Serious adverse reaction or serious hypersensitivity to any drug. * Presence of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab) or HIV 1 or HIV 2 antibodies at screening. * Administration of radiolabelled substances or exposure to significant radiation (eg serial x-ray or CT scans, barium meal etc) within the past 12 months. * Any ECG abnormality at screening (including QTc intervals of \>430 ms). * Past medical history of clinically significant ECG abnormalities, or a family history of a prolonged QT interval syndrome. * Abnormal diet or substantial changes in eating habits within 30 days prior to study initiation. * Treatment with any known enzyme altering agents (barbiturates, phenothiazines, cimetidine, etc.) within 2 months prior to or during the study.